Abstract
PK-SS-Hy-D drug-protein prodrug was obtained by conjugating doxorubicin (DOX) onto the PEGylated keratin (PK) with both bioreducible disulfide linkage and acid-cleavable hydrazone bond in a series connection mode. The controlled release profiles demonstrated the pH and reduction dual-responsive triggered release of DOX from the proposed drug-protein conjugate nanoparticles, with a low premature drug leakage of 5.5% in the simulated physiological medium. The in vitro experiments indicated that the proposed prodrug nanoparticles could delivery DOX into the cell nuclei, with an enhanced anti-tumor efficacy. It is expected as a potential candidate for future tumor chemotherapy with minimized toxic side effect.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
